|
Synonyms: CHI-621 | L04AC02 | SDZ-CHI-621 | Simulect®
basiliximab is an approved drug (FDA (1998), EMA (1998))
Compound class:
Antibody
Comment: Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
View more information in the IUPHAR Pharmacology Education Project: basiliximab |
| References |
|
1. Amlot PL, Akbar AN, Heinrich G, Cammisuli S. (2002)
Methods Of Treatment Using Cd25 Binding Molecules. Patent number: US6383487. Assignee: Novartis Ag, University College London. Priority date: 16/03/1990. Publication date: 07/05/2002. |
